Skip to main content
OpenTrials
Completed

NCT Number: NCT01800305

PK & PD Study of Pegylated rhEPO, and Evaluated Its Safety and Tolerability in Male Healthy Individual

The object of this randomized, parallel, positive controlled study is to explore the pharmacokinetics and pharmacodynamics profile of the test drug after single-dose subcutaneous administration, compared to the comparator drug (EPIAO®) after multiple-dose subcutaneous administration, by assessing plasma concentration of the drug and the reticulocyte count, hemoglobin concentration and hematocrit following subcutaneous administration, evaluate the security and tolerability of the test drug in healthy subjects, and provide sufficient information for dose selection in the future phase II and III study.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy

Age range

18 year–40 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

302 Military Hospital of China

Beijing, China

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Agree to all the purposes of the study by signing and dating the informed consent.
  • Male, aged between 18 and 40 years, age disparity of each group should less than 10 years.
  • Body weight ≥ 50kg, and body mass index (BMI) between 18 kg/m2 and 26kg/m2 at screening.
  • Hemoglobin between 131g/L and 162g/L, hematocrit between 41% and 49%, and reticulocyte between 0.5% and 2%.
  • Transferrin saturation and serum ferritin are in the normal range.
  • Physical condition: vital signs, physical examination and laboratory tests ( including routine blood, biochemical tests, coagulation indicators, serum folic acid, vitamin B12, urine test, HBsAg, anti-HCV, anti-HIV, Immunoglobulin (IgA, IgM, IgG), thyroid function (T3, T4, TSH), autoantibodies), chest-X-ray, 12-lead ECG should all in normal range, or without significant clinically abnormal.

Exclusion criteria

  • Presence of organic disease in heart, liver, kidney, brain; or presence of cardiovascular, pulmonary, gastrointestinal, urinary, neurological, endocrine, immunity, genitourinary or other systems disease.
  • Subjects with familial genetic disease, mental illness, or physical disability.
  • History of drug allergy.
  • Orthostatic hypotension, systolic blood pressure <90mmHg.
  • Habitual medication, including Chinese herbal medicine.
  • Poor inclusion conditions (e.g. infirm).
  • Smoker (smoke everyday or more than 7 cigarettes per week)，alcoholics (more than 40g/day, equivalent to 100ml/day of 50 degree of white spirit).
  • Participate in any other drug trials as the subjects within the previous 3 months.
  • As blood donated within the previous 3 months, or experienced massive blood loss due to trauma or surgery.
  • Other conditions which in the opinion of the investigator precluding enrollment into the study (e.g. poor compliance).

Treatment and study plan

Pegylated rhEPO

Drug

EPIAO®

Drug

Primary outcomes

  1. Serum concentration of rhEPO

    Time frame: 0 hour before drug administration and 1, 3, 6, 9, 12, 14, 16, 24, 36, ,48, 72, 96, 120, 144, 168, 192, 216,240, 264, 288, 300, 312, 360, 408, 480, 648, 984,1320 hour after drug administration

    • Time frame of day 12 for comparator drug: 0 hour before drug administration and 1, 3, 6, 9, 14, 16 hour after last dose administration.
    • For comparator drug, blood collection of 0, 48, 96, 168, 216, and 264 hour should before drug administration.

  2. Plasma reticulocyte count

    Time frame: 0 hour before and 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 360, 408, 480, 648,984,1320 hour after first drug administration.

    For comparator drug, blood collection of 48, 96, 168, 216, and 264 hour should before drug administration

  3. Plasma hemoglobin concentration

    Time frame: 0 hour before and 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 360, 408, 480, 648,984,1320 hour after first drug administration.

    For comparator drug, blood collection of 48, 96, 168,216, and 264 hour should before drug administration

  4. Plasma hematocrit

    Time frame: 0 hour before and 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 360, 408, 480, 648,984,1320 hour after first drug administration.

    For comparator drug, blood collection of 48, 96, 168,216, and 264 hour should before drug administration

Sponsors and collaborators

Lead sponsor

Xiamen Amoytop Biotech Co., Ltd.

Industry

Registry information

Official study title

A Randomized, Positive-controlled, Single-dose, Dose-escalation Phase I Trial to Evaluate Safety & Tolerability, and Explore the Pharmacokinetics and Pharmacodynamics Profile of Pegylated rhEPO in Male Healthy Individual

Important dates

Study start
2012
Primary completion
2014
Study completion
2014
First posted
Feb 27, 2013
Registry last updated
Aug 31, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.